Xilio Therapeutics (NASDAQ:XLO) Stock Price Down 0.5% – Here’s What Happened

Xilio Therapeutics, Inc. (NASDAQ:XLO) shares traded down 0.5% on Friday . The company traded as low as $0.6550 and last traded at $0.6619. 218,489 shares traded hands during trading, a decline of 57% from the average session volume of 504,235 shares. The stock had previously closed at $0.6653.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Xilio Therapeutics in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $2.00.

Xilio Therapeutics Price Performance

The stock has a market capitalization of $34.75 million, a price-to-earnings ratio of -1.02 and a beta of -0.07. The firm’s fifty day moving average is $0.74 and its 200-day moving average is $0.73.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). The company had revenue of $19.07 million during the quarter, compared to analyst estimates of $18.64 million. Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. On average, sell-side analysts expect that Xilio Therapeutics, Inc. will post -1.14 EPS for the current year.

Institutional Trading of Xilio Therapeutics

An institutional investor recently bought a new position in Xilio Therapeutics stock. ADAR1 Capital Management LLC bought a new position in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 40,000 shares of the company’s stock, valued at approximately $29,000. ADAR1 Capital Management LLC owned about 0.08% of Xilio Therapeutics as of its most recent SEC filing. Institutional investors own 54.29% of the company’s stock.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.